GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Cyclically Adjusted PS Ratio

ABBV (AbbVie) Cyclically Adjusted PS Ratio : 6.50 (As of Jul. 06, 2025)


View and export this data going back to 2012. Start your Free Trial

What is AbbVie Cyclically Adjusted PS Ratio?

As of today (2025-07-06), AbbVie's current share price is $189.28. AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $29.14. AbbVie's Cyclically Adjusted PS Ratio for today is 6.50.

The historical rank and industry rank for AbbVie's Cyclically Adjusted PS Ratio or its related term are showing as below:

ABBV' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.91   Med: 6.26   Max: 8.05
Current: 6.5

During the past years, AbbVie's highest Cyclically Adjusted PS Ratio was 8.05. The lowest was 4.91. And the median was 6.26.

ABBV's Cyclically Adjusted PS Ratio is ranked worse than
85.07% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.18 vs ABBV: 6.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AbbVie's adjusted revenue per share data for the three months ended in Mar. 2025 was $7.530. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $29.14 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


AbbVie Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AbbVie's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Cyclically Adjusted PS Ratio Chart

AbbVie Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.12 6.55 6.79 5.93 6.25

AbbVie Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.76 6.24 7.05 6.25 7.19

Competitive Comparison of AbbVie's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PS Ratio falls into.


;
;

AbbVie Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AbbVie's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=189.28/29.14
=6.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, AbbVie's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=7.53/134.9266*134.9266
=7.530

Current CPI (Mar. 2025) = 134.9266.

AbbVie Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 3.353 100.684 4.493
201509 3.572 100.392 4.801
201512 3.895 99.792 5.266
201603 3.666 100.470 4.923
201606 3.953 101.688 5.245
201609 3.922 101.861 5.195
201612 4.182 101.863 5.539
201703 4.079 102.862 5.351
201706 4.340 103.349 5.666
201709 4.364 104.136 5.654
201712 4.819 104.011 6.251
201803 4.971 105.290 6.370
201806 5.266 106.317 6.683
201809 5.436 106.507 6.887
201812 5.533 105.998 7.043
201903 5.278 107.251 6.640
201906 5.563 108.070 6.945
201909 5.717 108.329 7.121
201912 5.853 108.420 7.284
202003 5.808 108.902 7.196
202006 6.330 108.767 7.852
202009 7.273 109.815 8.936
202012 7.781 109.897 9.553
202103 7.330 111.754 8.850
202106 7.860 114.631 9.252
202109 8.071 115.734 9.409
202112 8.363 117.630 9.593
202203 7.614 121.301 8.469
202206 8.211 125.017 8.862
202209 8.340 125.227 8.986
202212 8.490 125.222 9.148
202303 6.883 127.348 7.293
202306 7.829 128.729 8.206
202309 7.864 129.860 8.171
202312 8.052 129.419 8.395
202403 6.943 131.776 7.109
202406 8.166 132.554 8.312
202409 8.160 133.029 8.276
202412 8.503 133.157 8.616
202503 7.530 134.927 7.530

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AbbVie  (NYSE:ABBV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AbbVie Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AbbVie's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie Business Description

Industry
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Executives
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Robert A. Michael officer: VP, Controller 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064

AbbVie Headlines

From GuruFocus